Neural retinal impairment linked to flicker light response

Article

The impairment of vascular response to flicker lights could reveal inner retinal neural impairment in patients with diabetic retinopathy (DR)

The impairment of vascular response to flicker lights could reveal inner retinal neural impairment in patients with diabetic retinopathy (DR), according to a study published in Investigative Ophthalmology and Visual Science.

Dr Pascale Massin et al., Department of Ophthalmology, Lariboisière Hospital, Paris, France, studied 28 normotensive, diabetic patients wihout DR and 28 healthy patients of the same age and sex as the control group. All patients underwent colour vision and contrast sensitivity tests, evaluation of the vascular reponse to flicker lights with the dynamic vessel analyser (DVA) and pattern, full field and multifocal electroretinogram (ERG).

It was found that diabetic patients experienced significantly impaired ERG pattern responses in comparison with the healthy subjects. This included the b-wave in the scotopic bright flash ERG, the a-wave and b-wave in the photopic single flash ERG. The vascular response to flicker light in diabetic patients compared to the control group was impaired.

Correlations were discovered between flicker light-induced arterial retinal vasodilation and the amplitude and implied times of the N95 wave of pattern ERG throughout the whole study group.

No strong correlation was found between the result of the diabetic patients, but it was concluded that neural and neovascular dysfunctions come before the start of clinically detectable DR.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.